Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Immunoproteasome subunit beta type-9 (LMP2)
- Target
- LMP2
- Molecular classification
- Enzyme, Proteasome subunit
01
Overview
Immunoproteasome subunit LMP2 (β1i or PSMB9) is a catalytically active component of the immunoproteasome, a specialized proteasome complex crucial for immune function. It replaces the standard proteasomal subunit β1, conferring chymotrypsin-like activity and enhancing the generation of antigenic peptides for MHC class I presentation to CD8+ T cells. LMP2 is upregulated by IFNγ and is involved in NF-kB signaling. Altered expression or function is implicated in autoimmunity, cancer, neurodegeneration, and cardiovascular diseases, making it a potential therapeutic target. Selective inhibitors like UK-101 and dual LMP7/LMP2 inhibitors are under development.
- Other names
- β1iPSMB9Large multifunctional peptidase 2
02
Mechanism of action
Selective inhibition of chymotrypsin-like activity within the immunoproteasome.
03
Biological functions
Antigen processing and presentationProtein degradationImmune responseNF-kB signaling
04
Disease associations
AutoimmunityCancerNeurodegenerative diseaseCardiovascular diseaseInflammationImmune Thrombocytopenia Purpura (ITP)
05
Safety considerations
Potential for off-target effects if inhibitors are not highly selective.Immunosuppression
06
Interacting drugs
UK-101
1 more in the full profile.
Beyond the preview
Go deeper on Immunoproteasome subunit beta type-9 (LMP2).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Immunoproteasome subunit beta type-9 (LMP2).